🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Italian banks boost European shares on prospect of new elections

Published 28/05/2018, 08:55
© Reuters. FILE PHOTO: Traders work at their desks in front of the German share price index, DAX board, at the stock exchange in Frankfurt
UK100
-
DE40
-
ES35
-
IT40
-
UBI
-
BBVA
-
CABK
-
NTGY
-
IBE
-
SAN
-
GMAB
-
ISP
-
CRDI
-
ENEI
-
BAMI
-
FTITLMS3010
-
STOXX
-

LONDON (Reuters) - Italian banks led a sharp European stocks rebound on Monday after the failure of anti-establishment parties to form a government lifted the euro zone's peripheral markets with the prospect of fresh elections.

The Five-Star and League parties abandoned efforts to form a government after Italy's President vetoed their choice of a eurosceptic economy minister, sending Italian bond yields lower and Italy's main FTSE MIB stock index sharply higher, while the euro also made gains.

The FTSE MIB (FTMIB) had climbed 1.4 percent by 0720 GMT as financials and utilities stocks surged.

Italy's banks index (FTIT8300) jumped 3.1 percent, set for its biggest gain since January. Unicredit (MI:CRDI), UBI Banca (MI:UBI), Banco BPM (MI:BAMI) and Intesa Sanpaolo (MI:ISP) rose 2.2 to 2.8 percent.

Utility Enel (MI:ENEI), which had also been hurt by investors pricing in some of the coalition's policies on renewable energy, traded up 1.9 percent.

Banks fuelled a 0.2 percent gain in Europe's STOXX 600 (STOXX), while Germany's DAX (GDAXI) rose 0.5 percent. Britain's FTSE 100 (FTSE) was closed for a holiday and with U.S. markets also closed, trading volumes were thinner.

Spain's IBEX (IBEX) also rose 0.7 percent as the rally spread to other southern European markets. Spanish stocks had fallen sharply on Friday on concerns Prime Minister Rajoy would face a no confidence vote.

Financials and utilities led the recovery in Spain too, with Santander (MC:SAN), BBVA (MC:BBVA) and Caixabank (MC:CABK) top gainers along with Iberdrola (MC:IBE) and Gas Natural (MC:GAS).

© Reuters. FILE PHOTO: Traders work at their desks in front of the German share price index, DAX board, at the stock exchange in Frankfurt

Danish biotech firm Genmab (CO:GEN) fell 24 percent after it ended combination trials of its multiple myeloma drug Darzalex with Tecentriq, citing "no observed benefit" and an increase in deaths after the combination treatment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.